IO Biotech Statistics
Total Valuation
IO Biotech has a market cap or net worth of $72.47 million. The enterprise value is -$5.70 million.
Important Dates
The next estimated earnings date is Tuesday, March 4, 2025, after market close.
| Earnings Date | Mar 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IO Biotech has 65.88 million shares outstanding. The number of shares has increased by 92.75% in one year.
| Current Share Class | 65.88M |
| Shares Outstanding | 65.88M |
| Shares Change (YoY) | +92.75% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 15.84% |
| Float | 31.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.00 |
| P/TBV Ratio | 1.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.37 |
| Quick Ratio | 5.05 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -78.50% and return on invested capital (ROIC) is -51.33%.
| Return on Equity (ROE) | -78.50% |
| Return on Assets (ROA) | -45.91% |
| Return on Invested Capital (ROIC) | -51.33% |
| Return on Capital Employed (ROCE) | -130.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, IO Biotech has paid $1.35 million in taxes.
| Income Tax | 1.35M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.49% in the last 52 weeks. The beta is 0.24, so IO Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -29.49% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 1.13 |
| Relative Strength Index (RSI) | 68.70 |
| Average Volume (20 Days) | 120,663 |
Short Selling Information
The latest short interest is 35,166, so 0.05% of the outstanding shares have been sold short.
| Short Interest | 35,166 |
| Short Previous Month | 48,532 |
| Short % of Shares Out | 0.05% |
| Short % of Float | 0.11% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -96.42M |
| Pretax Income | -87.64M |
| Net Income | -90.34M |
| EBITDA | -96.17M |
| EBIT | -96.42M |
| Earnings Per Share (EPS) | -$1.37 |
Full Income StatementBalance Sheet
The company has $80.19 million in cash and $2.02 million in debt, giving a net cash position of $78.17 million or $1.19 per share.
| Cash & Cash Equivalents | 80.19M |
| Total Debt | 2.02M |
| Net Cash | 78.17M |
| Net Cash Per Share | $1.19 |
| Equity (Book Value) | 72.57M |
| Book Value Per Share | 1.10 |
| Working Capital | 70.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$85.52 million and capital expenditures -$145,000, giving a free cash flow of -$85.66 million.
| Operating Cash Flow | -85.52M |
| Capital Expenditures | -145,000 |
| Free Cash Flow | -85.66M |
| FCF Per Share | -$1.30 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |